Transplantation: BENEFIT of belatacept: kidney transplantation moves forward
Nature Reviews Nephrology 12, 261 (2016).
doi:10.1038/nrneph.2016.34
Authors: Maarten Naesens & Olivier Thaunat
New data from the BENEFIT study demonstrate that belatacept improves long-term allograft and patient survival after kidney transplantation, despite higher rates of biopsy-proven acute rejection than with ciclosporin. The noninferiority design of BENEFIT represents a feasible strategy to further the development of innovator drugs to reduce late graft loss.
Source: Nature Reviews Nephrology - Category: Urology & Nephrology Authors: Maarten NaesensOlivier Thaunat Tags: News and Views Source Type: research
More News: Bone Graft | Kidney Transplant | Kidney Transplantation | Study | Transplants | Urology & Nephrology